---
title: "Annexon, Inc. Q2 2026: Net loss $55.3M — 10-Q Summary"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/295703881.md"
description: "Annexon, Inc. reported a net loss of $55.3M for Q2 2026, widening from $49.2M in the prior year period, with no product revenue generated. The company highlighted clinical progress on Tanruprubart (Phase 3 GBS), expanded Vonaprument Phase 3 endpoints, and completed dosing for ANX1502. Operational readiness increased via contract manufacturing for vonaprument technology transfer."
datetime: "2026-08-12T20:11:01.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/295703881.md)
  - [en](https://longbridge.com/en/news/295703881.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/295703881.md)
generator: "portal-rs"
---

# Annexon, Inc. Q2 2026: Net loss $55.3M — 10-Q Summary

Annexon, Inc. reported a net loss of $55.3M for the second quarter of 2026 and did not report product revenue for the period as it has not yet generated revenue from product sales.

**Financial Highlights**

-   Revenue: Not reported for the quarter (no product revenue; the company states it has not generated any revenue from product sales).
-   Net income: Net loss of $55.3M for Q2 2026, compared with a net loss of $49.2M in Q2 2025.
-   Diluted EPS: Not provided (diluted EPS not disclosed in Part I Items 1–2 of this 10‑Q).

**Business Highlights**

-   Clinical progress: Tanruprubart Phase 3 showed rapid, sustained improvement in Guillain‑Barré syndrome (GBS); a Marketing Authorization Application was filed with the EMA and the company plans FDA engagement ahead of a BLA submission in Q4 2026.
-   Late‑stage program expansion: Vonaprument Phase 3 ARCHER II added a Month‑24 dual primary endpoint and an open‑label extension to assess longer‑term vision protection.
-   POC and formulation work: ANX1502 oral program completed CAD dosing achieving target drug levels; an enteric‑coated tablet is under evaluation with a proof‑of‑concept update expected in H2 2026.
-   Operational readiness: Increased contract manufacturing activity to support vonaprument technology transfer to a commercial‑ready facility and continued global trial execution with low discontinuation rates.

Original SEC Filing: Annexon, Inc. \[ ANNX \] - 10-Q - Aug. 12, 2026

**Disclaimer**

This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.

### Related Stocks

- [ANNX.US](https://longbridge.com/en/quote/ANNX.US.md)

## Related News & Research

- [Annexon CEO Love joins fireside chats at September investor conferences](https://longbridge.com/en/news/297781969.md)
- [Annexon says tanruprubart shows rapid strength gains in first 10 GBS FORWARD study patients](https://longbridge.com/en/news/295104705.md)
- [PulteGroup declares Q3 2026 dividend of R$ 0.9 per unit](https://longbridge.com/en/news/297931957.md)
- [J.M. Smucker announces dividend of R$ 1.94 per unit for Q3 2026](https://longbridge.com/en/news/297931100.md)
- [LyondellBasell announces dividend of R$ 1.72 per unit for 3Q 2026](https://longbridge.com/en/news/297814383.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**